JW (Cayman) Therapeutics Co Ltd
HKEX:2126
Intrinsic Value
JW (Cayman) Therapeutics Co. Ltd. operates as a clinical stage cell therapy platform company. [ Read More ]
The intrinsic value of one JW (Cayman) Therapeutics Co Ltd stock under the Base Case scenario is 8.17 HKD. Compared to the current market price of 1.83 HKD, JW (Cayman) Therapeutics Co Ltd is Undervalued by 78%.
Valuation Backtest
JW (Cayman) Therapeutics Co Ltd
Run backtest to discover the historical profit from buying and selling JW (Cayman) Therapeutics Co Ltd stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
JW (Cayman) Therapeutics Co Ltd
Current Assets | 1.3B |
Cash & Short-Term Investments | 1.3B |
Receivables | 18.1m |
Other Current Assets | 50.2m |
Non-Current Assets | 1.3B |
PP&E | 371.6m |
Intangibles | 916.7m |
Other Non-Current Assets | 22.9m |
Current Liabilities | 348.6m |
Accounts Payable | 6.8m |
Accrued Liabilities | 44.2m |
Other Current Liabilities | 297.5m |
Non-Current Liabilities | 163.4m |
Long-Term Debt | 163.4m |
Earnings Waterfall
JW (Cayman) Therapeutics Co Ltd
Revenue
|
167.4m
CNY
|
Cost of Revenue
|
-87m
CNY
|
Gross Profit
|
80.4m
CNY
|
Operating Expenses
|
-745.2m
CNY
|
Operating Income
|
-664.8m
CNY
|
Other Expenses
|
-132.5m
CNY
|
Net Income
|
-797.3m
CNY
|
Free Cash Flow Analysis
JW (Cayman) Therapeutics Co Ltd
What is Free Cash Flow?
Profitability Score
Profitability Due Diligence
JW (Cayman) Therapeutics Co Ltd's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
JW (Cayman) Therapeutics Co Ltd's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
JW (Cayman) Therapeutics Co Ltd's solvency score is 55/100. The higher the solvency score, the more solvent the company is.
Score
JW (Cayman) Therapeutics Co Ltd's solvency score is 55/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
JW (Cayman) Therapeutics Co Ltd
According to Wall Street analysts, the average 1-year price target for JW (Cayman) Therapeutics Co Ltd is 3.43 HKD with a low forecast of 2.93 HKD and a high forecast of 4.01 HKD.
Shareholder Return
Price
JW (Cayman) Therapeutics Co Ltd
Average Annual Return | -31.64% |
Standard Deviation of Annual Returns | 46.71% |
Max Drawdown | -97% |
Market Capitalization | 740.6m HKD |
Shares Outstanding | 411 535 008 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
JW (Cayman) Therapeutics Co. Ltd. operates as a clinical stage cell therapy platform company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-11-03. The firm is focuses on developing cell therapies for the China market to transform the treatment of cancer for Chinese patients. Through its subsidiary, it has built an integrated platform focused on developing, manufacturing and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its main product candidate, relmacabtagene autoleucel (relma-cel), is an autologous anti-CD19 CAR-T therapy for relapsed or refractory (r/r) B-cell lymphoma. The firm mainly conducts its businesses in the China market.
Contact
IPO
Employees
Officers
The intrinsic value of one JW (Cayman) Therapeutics Co Ltd stock under the Base Case scenario is 8.17 HKD.
Compared to the current market price of 1.83 HKD, JW (Cayman) Therapeutics Co Ltd is Undervalued by 78%.